蒽环类药物普通制剂及脂质体制剂的心脏毒性研究进展  

Research progress of cardiotoxicity of conventional and liposomal anthracyclines

作　　者：高翠霞 王蕾 白彬 李晓晶 彭悦颖 张聪聪 胡子鉴 吕承 李海燕[5] GAO Cuixia;WANG Lei;BAI Bin;LI Xiaojing;PENG Yueying;ZHANG Congcong;HU Zijian;LV Cheng;LI Haiyan(Department of Medicine, CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang);Co., Ltd., Shanghai 200040, China)

机构地区：[1]石药集团中奇制药技术(石家庄)有限公司医学部,上海200040 [2]石药集团中奇制药技术(石家庄)有限公司医学部,050035 [3]石药集团中奇制药技术(石家庄)有限公司转化医学部,200040 [4]上海联拓生物科技有限公司,201204 [5]北京大学第三医院心血管内科,100191

出　　处：《临床肿瘤学杂志》2022年第1期88-93,共6页Chinese Clinical Oncology

摘　　要：蒽环类药物属于抗肿瘤抗生素,为细胞周期靶向非特异性药物,具有广谱、强效的特点,临床上广泛用于实体肿瘤和恶性血液系统肿瘤的治疗。但是,因为容易引起心脏毒性事件而使其临床应用受到了一定程度的限制。经多年研究表明,与蒽环类药物普通制剂相比,脂质体制剂不但疗效相当,而且能减轻心脏毒性。本文就蒽环类药物普通制剂和脂质体制剂心脏毒性的流行病学、发生机制和防治措施作一综述,以期为其临床应用提供指导。Anthracyclines,antitumor antibiotics,and cell cycle targeted nonspecific drugs with broad-spectrum and high anti-tumor activity,have been widely used in solid tumors and hematologic malignancies.Their clinical use,however,is sometimes limited by the development of cardiotoxicity.Liposomal anthracyclines can decrease cardiotoxicity without decreasing the efficacy.This paper overviews the epidemiology,mechanism,prevention and treatment of cardiotoxicity of anthracycline common preparations and liposomes,in order to provide guidance for their clinical application.

关 键 词：蒽环类药物 脂质体蒽环类药物 心脏毒性 

分 类 号：R730.6[医药卫生—肿瘤]